NYSE:CBM - Cambrex Stock Price, News, & Analysis

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

Cambrex Co. (NYSE:CBM) posted its earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to analyst estimates of $132.78 million. Cambrex had a return on equity of 22.32% and a net margin of 20.75%. The company's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.76 earnings per share. View Cambrex's Earnings History.

Cambrex is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Cambrex.

Cambrex issued an update on its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share guidance of 2.91-3.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.85.

3 brokerages have issued 12 month target prices for Cambrex's shares. Their predictions range from $60.00 to $60.00. On average, they expect Cambrex's share price to reach $60.00 in the next year. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Cambrex.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.

Some companies that are related to Cambrex include Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amneal Pharmaceuticals (AMRX), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Catalent (CTLT), Ligand Pharmaceuticals (LGND), GALAPAGOS NV/S (GLPG), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO) and Taro Pharmaceutical Industries (TARO).

News articles about CBM stock have trended positive this week, Accern reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cambrex earned a media and rumor sentiment score of 0.33 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.40 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Cambrex.

Cambrex's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.90%), Bank of New York Mellon Corp (4.47%), Dimensional Fund Advisors LP (4.27%), American Capital Management Inc. (2.19%), Boston Partners (2.12%) and Brown Advisory Inc. (1.98%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Institutional Ownership Trends for Cambrex.

CBM stock was sold by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Eqis Capital Management Inc., Granite Investment Partners LLC, US Bancorp DE, Connor Clark & Lunn Investment Management Ltd., Peregrine Capital Management LLC, Royce & Associates LP and King Luther Capital Management Corp. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex.

CBM stock was acquired by a variety of institutional investors in the last quarter, including Investment Counselors of Maryland LLC, BlackRock Inc., Wells Fargo & Company MN, Acadian Asset Management LLC, FMR LLC, Rice Hall James & Associates LLC, Cambiar Investors LLC and Millennium Management LLC. View Insider Buying and Selling for Cambrex.

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBM stock can currently be purchased for approximately $63.70.

Cambrex has a market capitalization of $2.11 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]